Summary
Superficial transitional cell carcinoma of the bladder is a heterogeneous group of tumours, and prediction of disease outcome in an individual patient is still impo ssible . In low-risk patients the initial treatment [transurethral resection (TUR)] should be followed by no or only one immediate intravesical instillation with a chemotherapeutic drug to prevent a recurrence due to tumour cell implantation during TUR. Drug efficacy has been clearly demonstrated and adverse effects are very limited. Intermedi ate-risk patient s should receive a course of additional intravesical instillations to reduce the recurrence rate with few adverse effects. All drugs seem to be equally effective, but the long term effects remain a question. In high-risk patient s intrave sical immunotherapy (BeG) should be given . Although toxicity is more pronounced, it is usually mild and adverse effects disappear after cessation oftherapy. BeG (maintenance) therapy seems to be able to improve progression and ultimately tumour-related survival. It is important to know the advantag es and disadvantages (adverse effects) of these treatment modalities to be able to individualise treatment as much as possible. The choice is difficult because several intravesical bladder cancer trials have not reached consensus on this.
For patients with non-metastasised invasive bladder tumours chemotherapy can be given before (neoadjuvant) or immediately after (adjuvant) surgery or radiotherapy. Both strategies have some advantages and disadvantages . For both, however, efficacy still needs to be proven, and results of ongoing trials are needed. For metastasised or recurrent urothelial cell carcinoma MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy remains the most effective treatment modality. Although initial response rates of between 40% and 70% can be achieved, most patients have a recurrence of their cancer. Moreover, toxicity of these drugs also is considerable and limiting. Leucopenia is responsible for the majority of grade III and IV toxicities and subsequent dose modifications . In case of toxic deaths, a leucopenic sepsis is usually the cause. Most other adverse effects are acceptable or can be treated.
Bladder cancer is the second most common malignancy of the urinary tract, and accounts for 2% of all malignancies. In 1993 52 300 cases were registered in the US, while the number who died of bladder cancer that year was 9900. In 1992 in the Netherlands a total of 3777 bladder tumours was registered, which accounted for 5.7% of all malignancies.I!' Bladder cancer is predominantly seen in the sixth and seventh decade of life . The male to female ratio is approximately 4: I. These epidemiological data, however, are changing due to changes in the smoking behaviour among men and women .Pl
About two-thirds of bladder tumours will present as superficial [pTa (papillary noninvasive carcinoma, limited to the bladder mucosa), pTl (tumour not extending beyond the lamina propria of the bladder), carcinoma in situ (CIS; pre-invasive flat carcinoma)) transitional cell carcinomas (TCC»)3] The recurrence rate of these superficial tumours is high and depends on several factors . In our series of primary cases the 3-year risk of first recurrence ranged from 37% in low risk patients to 77% in high risk patients (overall nearly 55%). In a review of 6 historical series with long term follow up, the recurrence rates after 5, 10 and 15 years were 65%,81 % and 88%, respectively.If Most recurrences are found in the first years after transurethral resection (TUR) [5 1 and have the same stage and grade. These tumours can be true recurrences (regrowth after incomplete TUR or a result of im-© Adis Intemational Umited. All rights reserved.
plantation of tumour cells during TUR) and/or new occurrences. Prevention of implantation of the tumour is the rationale for immediate instillation of a chemotherapeutic drug.
The actuarial risk of disease progression in our series on bladder cancer patients was 10.2% after 3 years, with a 5-year relative survival rate of 86% . [3] This is in concordance with data from the literature.F'l With these data it is possible to select prognostic factors, like tumour grade and especially stage, recurrence rate, multiplicity, size and localisation. With such factors, three risk groups can be constructed: low-risk patients, a minority, have a low chance of recurrence, and almost no progression. An example is a primary, small, solitary, well to moderately differentiated pTa tumour; intermediate-risk patients comprise the largest group, and consist of patients who develop a superficial recurrence without obvious progression; and a small group of patients have high-risk tumours with a high recurrence rate and a chance of progression despite maximal intravesical treatment. Patients with multiple recurrent pTl grade 3 tumours and/or CIS belong to this last group.
Many other prognostic factors, like DNA ploidy, chromosomal abnormalities and marker chromosomes, have been described in the past few decades, but none .is able to predict recurrence or progression in an individual patient.F'
Initial Treatment
The cornerstone of the diagno sis of bladder cancer remains a TUR with or without mucosal biopsies. With this TUR specimen histology (> 90% TCq, tumour grade and stage can be determined. In case of a superficial bladder tumour a complete TUR with deep biopsies gives sufficient information to evaluate the need for additional treatment. These intrave sical instillations can be used to delay or prevent tumour recurrences (prophylaxis). In the case , however, of an incomplete resection (e.g. CIS), or contraindications against surgery, instillations are used to eradicate tumour (treatment) .
Advantages of the intravesical route of administration are limited systemic uptake of the drug with an optimal contact between the tumour or tissue at risk and the drug. Disadvantages are the local adverse effects in the bladder due to high local drug concentration and the need for transurethral manipulation. Instillations can be done with chemotherapeutic agent s or immunotherapeutic agents. In lowrisk patients the need for adju vant treatment is low.f S ] In the intermediate risk group intravesical instillations may be used to decrea se the recurrence rate. In patients with high-risk tumours intravesical immunotherapy could be considered , although the higher efficacy comes at a cost of more adverse effects.
Additional Therapy of Superficial Bladder Cancer

Intravesical Chemotherapy
Because most chemotherapeutic drugs are cell cycle-specific, repeated instillations seem more effective than single instillations. Although weekly or monthly instillations might be very practical, they are probably not ideal from a molecular biological (cell cycle) point of view.
For chemotherapeutic drug s, a molecular weight of less than 200 and subsequent systemic absorption and toxicity are important. Local adverse effects, like drug-induced cystiti s, are the main adver se effects, increa sing with the number and frequenc y of instillations and with the dose.
1 Thiotepa
Thiotepa is relati vely inexpensi ve and is not cell cycle specific . It has a low molecular weight of 189, and thus absorption and systemic toxicity can occur. Usually 30 to 60mg is used, although 30mg in 30ml seems to be as effective as 60mg in 60 ml.I?' After 6 weekly instillations treatment is generally continued for I year with monthly instillations.
Toxicity is mainly due to systemic absorption (leucopenia and thrombocytopenia in approximately 10%) and 25% of patients have irritative bladder complaints.UP'
In 10 small series, thiotepa as definitive therapy for papillary bladder tumours has had a moderate success rate (complete responders) of approximately 38% (109 of 285) . [11 ,12] In a large randomi sed trial (n = 379), no advantage of thiotepa was reported using single immediate instillations after a complete TUR.f 13] For other adjuvant treatment schedules Lamm [14) recently compared the recurrence rate of thiotepa (45%) to the recurrence rate in control groups (62%) in a series of 10 controlled studies with 1009 patient s. The results depended on the follow-up period and in 5 of the 10 series failed to reach statistical significance, including the 3 largest series. Two other large series also failed to show a statistically significant advantage for thiotepa, in spite of a lower recurrence rate in the treated patient s.f 15 ,1 6) In 2 other controlled studies thiotepa was proven to be . h d b" [17 IS] equally effective compared WIt oxoru ICIn. ' In summary. thiotepa is inexpensive, but its efficacy is questionable. Adverse effects such as myelosuppression and chemical cystitis are not frequent and usually mild .
1.2 Doxorubicin
Doxorubicin has a relatively high molecular weight of 580, and thus its absorption and systemic toxicity are extremely rare. The dose of doxorubicin ranges from 30 to 100mg in several instillation schedule s. Its main adverse effect is chemical cystitis in 25% of patients.[lO , 1 9] The average complete response rates of doxorubicin used as definitive treatment for papillary tumours was 38% (273 of 712), depending on the dose used.
[I2] For CIS the reported success rate was 63% (77 of 122), but the numbers were small.
In his review, Lamml 14] found no significant advantage of doxorubicin (recurrence rate of 38 versus 56% in control patients) in the prophylactic setting. The Japanese Urological Cancer Research Group found a significant advantage for doxorubicin with regard to recurrences, but they found no advantage of a maintenance schedule over a course of intravesical instillations.P'V"
In summary, in the treatment of bladder cancer patients, doxorubicin is a relatively safe drug with reversible chemical cystitis occurring in approximately 25% of the patients. The success rate of doxorubicin is slightly less than 40%, with a doubtful advantage over no additional treatment with the drug. Doxorubicin maintenance is clearly of no additional value.
'.3 Mitomycin
Mitomycin has a molecular weight of 329 and thus is absorbed only to a small extent. The dose varies between 20 and 60mg per instillation. In a recent review, the adverse-effects of leucopenia and thrombocytopenia were both found in only 4 of 613 (0.7%) patients.UP' A more frequent adverse effect is chemical cystitis, which is seen in approximately 15% of patients.Pl In our series, druginduced cystitis and (culture proven) bacterial cystitis were seen in 20 to 25% of the patients) 22 .23] Allergic reactions, mainly skin reactions such as palmar rash, are found in approximately 10%. [10.24] Most adverse effects disappear after cessation of therapy.
The overall success rates for definitive mitomycin therapy in papillary lesions is 43% (270 of 627) and for CIS 58% (51 of 88))12] For prophylactic . use, the advantage of mitomycin (15% higher success rate) over no treatment is not clear.
[I4] The advantage of mitomycin maintenance therapy is controversial.
In summary, systemic adverse effects for mitomycin are rare . The frequency of drug-induced cystitis is comparable to other chemotherapeutic drugs . In approximately 10% of the patients, (reversible) allergic reactions are seen. The response rates after mitomycin are around 50% and seem higher than of other chemotherapeutic agents. Our results with mitomycin have been better than the results in most other reports.
Etoglucid
Experience with etoglucid in superficial bladder cancer is limited . With a molecular weight of 262, it is poorly absorbed and systemic adverse effects are rare. The EORTC -GU group (study 30790) found exactly the same yearly recurrence rate (0.29) for intravesical therapy with doxorubicin (n = 165) and etoglucid (n = 156). [25] This was significantly better than the yearly recurrence rate of 0.65 in the control group (n = 70).
'.5 Epirubicin
Experience with epirubicin is increasing. To date, its reported adverse events seem mild. Mild chemical cystitis has been observed in approximately 15% of patients, while systemic toxicity appears to be absent. [26] In an EORTC study with a single immediate instillation of 80mg of epirubicin, chemical cystitis was only seen in 6.8% of patients.F" The efficacy of epirubicin was significantly better than that of sterile water in patients with a single superficial tumour (p < 0.0001).
In summary, toxicity of epirubicin seems limited to drug-induced cystitis and seems less frequent than with other drugs (15% or less). Results about the efficacy of epirubicin are as yet too preliminary.
Similarly, experience is very limited with other intravesical chemotherapeutics, such as cisplatin and mitoxantrone.
Several additional drugs have been used to improve the efficacy of intravesical chemotherapy.
In a bladder cancer cell line, an effort was made to improve cell kill by adding dimethyl sulfoxide (DMSO),!28] However, the addition of 4% DMSO to 4 frequently used intravesical drugs failed to improve cytotoxicity. Recently, it was even suggested that intravesical DMSO might promote bladder carcinogenesis in mice. 129] Verapamil is a calcium antagonist which can reverse multi-drug resistance (MDR). In vitro verapamil increased the cytotoxicity of doxorubicin by a factor of 2.5. [30] Preliminary clinical data on the intravesical use of verapamil, however, have shown it to confer neither an additional advantage, nor to produce increased toxicity.U!'
Intravesicallmmunotherapv
In 1976, the era of intravesical immunotherapy started with the introduction of intravesical bacillus Calmette-Guerin (BCG)
1 Interferon
Clinical experience to date with intravesical interferon in superficial bladder cancers is very limited . The optimal dose remains a question, and clinical results have been less than those observed with BCG. [33, 34] 
Bacillus Co/meffe-Guerin (BCG)
The mechanism of action of BCG remains unclear. There is a combination of a clear inflammatory effect (the nonimmunological response) and a nonspecific and specific immunological response (humoral and cellular).
The optimal dose seems to be 5 x 10 8 to 5 X 10 9 colony-forming units (CFU), although similar success rates, with less toxicity, have been reported with very low doses of BCG, 135-371 even in highrisk patientsJ38] Intravesical instillation of BCG is accepted as the best route of administration. Combination with intradermal administration does not improve the results.P'" After a complete TUR of a superficial tumour, the initial schedule is a course of 6 weekly instillations. In high-risk patients (recurrences, CIS, etc.) , a second course of 6 instillations or maintenance therapy (e.g. monthly instillations for I year) can be given . Both regimens will improve the success rates . A second course seems most useful in patients who respond well to the initial course of BCG and ultimately have recurrent disease. However, in patients failing both courses, a significantly higher risk for muscle invasion by the cancer is found, so more aggressive therapy should be considered. Maintenance therapy has more local and systemic toxicity.[ 401 Local adverse effects (cystitis-like complaints) are found in over 90% of the patients and increase with the number of instillations.H'J They are easily treated with nonsteroidal anti-inflammatory drugs. Haematuria, although seldom severe, is seen in 43% of patients. Systemic adverse effects such as fever (28 %), malaise (24%) and nausea (8%) generally subside spontaneously. Severe adverse effects (fever >39.5°C, genital infections, haematuria, BCG pneumonia/hepatitis/sepsis) are seen in about 5% of all patients.l 4Z1 In these patients therapy should be stopped, and eventually antituberculous therapy should be started. Only few fatal complications have been encountered, and traumatic catheterisation seems to play an important role in these cases. Therefore, treatment should be postponed for one week in case of a traumatic catheterisation.
The clinical results of BCG have been good. With BCG the recurrence rate of more than 60% without additional therapy decreases to 35% or less with a minimal follow up of I year.l 401 BCG is superior to intravesical chemotherapy, but at the cost of inducing more adverse effects. A recent SWaG study, for example, showed a clear significant advantage of BCG over mitomycin.F'J In two of our own studies, however, this advantage of BCG could not be confirmed.!2 z,Z31 In fact, mitomycin toxicity was significantly less in our trials . Patient selection, prognostic profile and differences in treatment schedules and dose can partly explain these conflicting results .
After an incomplete endoscopic resection, BCG can be used as therapy, with success rates of 60 to 70%. In case of CIS, the success rates of BCG vary between 42 and 83% (patients at least I year free of recurrences as seen on cystoscopy and cytology») 401 Although at this moment BCG seems to be the drug of choice for high risk superficial TCC, many questions remain unanswered, especially about the mechanisms of action, the optimal dose and clinical schedule.
Dru g Therap y for Bladd er Can cer
Bropirimine
In high-risk patients failin g intravesical BCG , more aggressive treatment such as cys tec tomy seems inevitable because of the high risk of tumour progression to muscle invasive disease. For such patients oral bropirimine might be an alternative.
Bropirimine is a biological respon se modifier which influences both humoral and cell -medi ated immune responses. Its act ivit y approached that of BCG in an animal model. l44 ] Ad verse effect s are mainly mild to moderate ' flu-like sy mptoms (fev er, nau sea , fati gue and headache). Cardiac dy srh ythmias have been reported in patients with coexi sting cardiac di sea se. 145]
In superficial bladder can cer, a phase II study was performed with a do se of 3000 mg/day (amended from 4500 mg/day because of the cardiac dysrhythmiasj.I'v l In 47 evalu able patients, 26 complete re sponses (negative cysto scopy, cytolog y and biopsy) were seen (55%), also in some of the patients who were BCG failure s.
Long Term Efficacy Results In Superficial Bladder Cancer
In a review of long term results of intra vesical ch emotherapy, the short term cancer recurrence rate decre ased from 58 to 41 % in a gro up of 2,799 patients rece iving cancer chemoth erap y [thiotepa (n = 1009), mitomycin (n = 859), do xorubicin (n = A combination of controlled studies (1423 patients) also failed to dem onstrate an advantage: the progression rate was 6.6 % for treated patient s and 7.2% for controls. Although it rem ain s a que stion why obvious redu cti on of recurrenc e rates doe s not influence progression , an explan ation might be that intr avesical che motherapy doe s not reach the deeper layers of the bladder, where the potentially invasive tumours might originate.
BCG, on the other hand, seems to be the only drug whi ch also reduces tumour progression and even bladder canc er death) 14,49] Lamm, for example , observed an improv ed surv iva l in patients treated with maintenance therapy in responders to an initial 6-w eek course. Uf
Invasive Bladder Cancer
An intere sting approach is the use of primary (neoadj uvant) chem otherapy in patients with locally ad vanced (~pT2) bladder cancer. In spite of neg ative screening, man y of the se patients will have recurrent disease after treatment with curative inten t (radical surgery or radiotherap y) dependent on the initial stage of the tumour. It is also known that co mbinatio ns of che mothe rape utic agents based on cisplat in (C) and methotrexate (M) , with vinblastine (V) or with vinblastine and doxorubicin (A) can give respon se rate s of 55 to 70 %, with complete remi ssion s of 25 % or more for CM, CMV and MVAC)50-52] Theoretically, therefore, neoadjuvant che motherapy prior to loc al definitive therapy has potential adva ntages, as was shown in pha se II studies . 153] Th e first results of rand omi sed studies indicated that there might be some advantage of neoadjuvant che motherapy. A Nordic study, for exa mple, indicated a 15% overall survival advant age after neoadjuvant chemotherapy and cystectomy with a 5-year follow-up.Uf In a combined MRC/EORTC study, 975 patients with locally advan ced bladder cancer were randomised for no or 3 cycles of CMV Drug s 1997 Mar ; 53 (3) (cisplatin 100 mg/m", methotrexate 30 mg/m? and vinblastine 4 mg/m-; CMV) prior to definite surgicalor radiation therapy. Preliminary results after a median follow up of 22 months showed no difference in survival between neoadjuvant CMV or no CMV [Hazard ratio (HR) 0.95, P = 0.63].f55J Overall disease-free 2-year survival rates were 51 versus 45% (HR = 0.84, P = 0.06), but this might have been due to arm-dependent biases in the time to diagnosis of the progression. In patients treated with cystectomy, CMV appears to have clear activity on the primary tumour (33 versus 12% pathological complete responses). This was also found by Logothetis et al.f 56] They compared 5 postcystectomy courses of MVAC to a combination of 2 pre-and 3 postoperative courses . The second interim analysis showed no survival difference, but in the 'neoadjuvant' group 28 versus 2% pathological complete responders were seen (p = 0.004), improving local resectability or offering the possibility of organ preservation. In general, low tumour stage (pT2) and downstaging to pTOare important prognostic factors for neoadjuvant chemotherapy.
Compared with neoadjuvant treatment, immediate adjuvant chemotherapy for proven locally advanced disease has the advantage that the pathological stage is precisely known at the moment of the start of the chemotherapy. A disadvantage, however, is that there is no measurable disease. Moreover, bowel in the urinary tract can absorb chemotherapeutic agents if not drained. Skinner et aI. reported a randomised trial comparing adjuvant CISCA (cisplatin, cyclophosphamide and doxorubicin) treatment versus observation after radical cystectomy and lymph node dissection.f 57J In all, 91 patients with T3, T4 or N+MO tumours were randomised. There was a significant advantage in the treated group for time to progression (p = 0.001) and survival (p = 0.006), but the group was small and not uniform . Freiha et al. also found a progression advantage (freedom of progression 37 versus 12 months, p = 0.01) using 4 additional cycles of CMV in 50 patients with a median follow up of 62 months.P" However, they did not find a significant survival advantage (median survival 63 © Adls Intematlonal Umited. All rights reserved.
Witjes versus 36 months, p = 0.32), possibly because some relapsing patients could also be salvaged by CMV chemotherapy.
Treatment of Disseminated Bladder Cancer
We are regularly confronted with patients who already have metastasised bladder cancer or a relapse after intended curative treatment. In these patients chemotherapy should be considered.
Since the first report in 1985, the MVAC regimen is now widely used in urinary tract cancers . [59] The initial response rates were very promising [CR 50%, and partial response (PR) 21%]. In a followup study CR and PR rates were both 36%.f 60] Moreover, there was a significant survival advantage in the CR group: median survival of more than 38 months compared to 11 months in the PR group, and 8 months for the non-responders. The most favourable sites of metastases were lungs, followed by retroperitoneal lymph nodes and bone . In a randomised trial, Logothetis et al. found somewhat lower response rates, but response rates (p < 0.05) and survival (p = 0.0003) were significantly better than with CISCA.f 61] In another randomised trial MVAC was shown to be significantly superior to cisplatin monotherapy with regard to response rate and survival (p = 0.0002).f 62] In spite of these promising initial CR rates, however, the majority of patients in these series relapsed.
Toxicity of MVAC remains a major limiting factor. Different grades of myelotoxicity are seen in almost all patients, and subsequent treatmentrelated deaths due to a nadir sepsis have been reported. Other adverse effects are mucositis, nausea, vomiting, alopecia and renal toxicity. MVAC is significantly more toxic than cisplatin monotherapy.f 62] Toxicity data of some studies, including our own experience, are listed in table I. MCV is less toxic than MVAC, and is therefore also widely used. Efficacy of MVAC and MCV have, however, never been compared in a randomised study. Carboplatin is less toxic than cisplatin, but it also seems to be less effective.f 63] Myelotoxicity durin g MVAC therapy can be prevented or dimini shed with haematopoietic growth factor s, such as granulocyte-colony stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF). Moore et aU 64j found approximately 40 %~grade 3 granulocytopenia when the first 2 cycles of MVAC were comb ined with GM-CSF compared with 80% in their earlier experience. In addition, nadir platelet and granulocyte counts were significantly higher. An ongoing EORTC trial will give more insight in to the value of this regimen .
In patients relapsing after MVAC chemotherapy the possibilities are very limited . Based on some promi sing results of Logothetis,165] the EORTC has started a phase II trial to study the efficacy of a combination of fluorouracil, cisplatin and interferon-a as second-line therapy in patients with progressive metastatic transition al cell carcinoma of the urinary tract despite previou s chemotherapy. 
Conclusions and Recommendations
The question of drug therap y in superficial, invasive and metastasised bladder cancer remain s difficult because results of clinic al trials, to date, have not reached a consensus on all patients.
In patients with superficial bladder tumours at low risk for recurren ce and progre ssion, the initial transurethral resection should be followed by no or only one immediate intravesical instillation with a chemotherapeutic drug to prevent a recurrence due to tumour cell implantation durin g transurethral resection. Efficacy of this regimen has been clearl y demon strated and side effects have been very limited. Intermediate risk patients should receive a course of additional intravesical instillations with mitomycin to lower the recurrence rate. We have found mitomycin to be effective with few and reversible adverse effects. However, although all chemotherpeutic drugs appear to be equally effective on a short term basis, their long term (5 years and more) effects with regard to recurrence and progression remains a question . In high risk patients intravesical immunotherapy with BCG is the standard preferred treatment. Although toxicity with BCG is more pronounced, it is usually mild and reversible with cessation of drug therapy. Maintenance BCG therapy seems to be able to decrease the tumour progression rate and therefore improve tumour-related survival.
The value of neoadjuvant systemic chemotherapy in patients with non-metastasised invasive bladder tumours has not been proven . Adjuvant chemotherapy immediately after surgery or radiotherapy remains in the experimental stage, and thus results of ongoing trials are needed. For rnetastasised or recurrent urothelial cell carcinoma, MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) remains the most effective treatment modality despite considerable and limiting systemic toxicity (predominantly leucopenia). Initial response rates between 40 and 70% can be achieved, although most patients will ultimately suffer a recurrence of their cancer.
